Purpose: Therapeutic management of metastatic cancer patients who are hospitalized at the time of initial diagnosis because of impaired performance status and/or severe symptoms is challenging for clinicians. This study aims to describe their outcome. METHODS: In this prospective multicentric study, we included all adult, inpatients with newly diagnosed metastatic solid tumors between November 2021 and May 2022. Patients were followed for 3 months.. Our primary objective was to describe overall survival (OS). Secondary objectives included assessing SANT effectiveness in specific subgroups, identifying baseline factors associated with SANT initiation, and assessing usual prognostic tools and factors associated with response.
Results: 107 patients were included. Seventy-four (69%) initiated a SANT. Among them, 39 patients were alive at 3 months. Median overall survival was 1.7 months for the entire cohort. Thirty-seven patients (55%) died in the unit where they were first admitted. Patients with chemo-sensitive tumors, such as testicular non-seminomatous germ cell tumors (100% OS at 3 months), or those receiving targeted therapies or hormone therapies (80% OS at 3 months), showed numerically better outcomes. Factors associated with the initiation of a SANT were young age (OR = 0,94 [0,90; 0,98]), low Charlson Comorbidity Index (OR = 0,56 [0,42; 0,73]), and patient's or caregiver's request for treatment (respectively, OR = 0,07 [0,02; 0,17] and 0,17 [0,06; 0,42], compared to the respective reference category (no request)).
Conclusion: Metastatic cancer patients hospitalized at the time of diagnosis share a similar poor survival. Despite the notable exception of chemo-sensitive tumors and specific molecular alterations, the high mortality observed in both groups suggests that SANT has a limited impact on their outcomes. Best supportive care can be reasonably considered for these patients. The benefit of SANT in this altered population should be assessed in larger prospective studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00520-025-09202-5 | DOI Listing |
FASEB J
March 2025
Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin, China.
Breast cancer (BC) is one of the most common malignant tumors among women, accounting for 24.5% of all cancer cases and leading to 15.5% of cancer-related mortality.
View Article and Find Full Text PDFCancer Med
March 2025
Universidad Autónoma del Estado de Morelos, Facultad de Medicina, Cuernavaca, Morelos, Mexico.
Introduction: Osteosarcoma, a highly aggressive bone cancer primarily affecting children and young adults, remains a significant challenge in clinical oncology. Metastasis stands as the primary cause of mortality in osteosarcoma patients. However, the mechanisms driving this process remain incompletely understood.
View Article and Find Full Text PDFFront Med (Lausanne)
February 2025
Department of Gastroenterology II, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China.
Objective: This study aims to assess the mesenchymal-epithelial transition factor's (c-MET) prognostic value in oesophageal carcinoma (ESCA) through a meta-analysis and bioinformatics.
Methods: We analysed c-MET expression in ESCA tissues using data from The Cancer Genome Atlas (TCGA) and conducted a meta-analysis to evaluate its association with clinicopathological factors and survival outcomes. The meta-analysis included studies reporting hazard ratios (HRs) and odds ratios (ORs) for survival and metastatic outcomes.
J Med Econ
December 2025
Adelphi Values PROVE, Bollington, UK.
Introduction: Melanoma, responsible for most skin cancer deaths globally, has mortality rates expected to double by 2040. Pembrolizumab is a highly selective antibody approved for melanoma treatment and other cancers. Despite new treatments for melanoma, high treatment costs and long approval times limit patient access to new therapies.
View Article and Find Full Text PDFJ Turk Ger Gynecol Assoc
March 2025
Metaxa Memorial Cancer Hospital, Piraeus, Greece.
Currently, there is limited information available on the best course of action for advanced epithelial ovarian cancer (OC) with isolated extra-peritoneal disease in the cardiophrenic lymph nodes. Recently, there have been numerous reports of successful surgical removal of metastatic cardiophrenic lymph nodes in patients with OC, mostly during primary or interval cytoreduction procedures. However, the optimal management of isolated, extra-peritoneal cardiophrenic lymph node metastasis (ICLNM) remains unclear, since this clinical scenario is rather uncommon in OC and chemotherapy is so far the indicated treatment for patients with from advanced stage disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!